Zhu, remdesivir meta analysis: 36% lower mortality [p=0.02] https://c19p.org/zhu
copied to clipboard
Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
et al., medRxiv, doi:10.1101/2020.06.22.20136531
(Preprint) (meta analysis)
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).Currently there are
36 remdesivir
for COVID-19 studies, showing 19% [10‑27%] lower mortality, 24% [-5‑61%] higher ventilation, 34% [-6‑92%] higher ICU admission, and 39% [-36‑201%] higher hospitalization.
|
risk of death, 36.0% lower, RR 0.64, p = 0.02.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Zhu et al., 6/29/2020, preprint, 11 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.